Arcutis logo.png
Arcutis Promotes Todd Tucker to Chief Human Resources Officer
March 11, 2024 08:00 ET | Arcutis Biotherapeutics, Inc.
Arcutis today announced the promotion of Todd Tucker to senior vice president and Chief Human Resources Officer.
Arcutis logo.png
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
March 10, 2024 16:00 ET | Arcutis Biotherapeutics, Inc.
Investigational roflumilast cream 0.05% met the primary endpoint and all secondary endpoints, showing significant improvement
Arcutis logo.png
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
March 09, 2024 16:00 ET | Arcutis Biotherapeutics, Inc.
These findings are the first to characterize the unique molecular profile of seborrheic dermatitis
Arcutis logo.png
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 05, 2024 16:00 ET | Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...
Arcutis logo.png
Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
March 04, 2024 16:00 ET | Arcutis Biotherapeutics, Inc.
Arcutis today announced the closing of its previously announced underwritten public offering.
Arcutis logo.png
Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting
March 04, 2024 08:00 ET | Arcutis Biotherapeutics, Inc.
Arcutis today announced five presentations at the 2024 American Academy of Dermatology (AAD) annual meeting.
Arcutis logo.png
Arcutis to Present at the TD Cowen 44th Annual Health Care Conference
February 29, 2024 17:00 ET | Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...
Arcutis logo.png
Arcutis Announces Pricing of $150 Million Public Offering
February 28, 2024 23:30 ET | Arcutis Biotherapeutics, Inc.
Arcutis today announced the pricing of its underwritten public offering of common stock.
Arcutis logo.png
Arcutis Announces Proposed Public Offering
February 28, 2024 16:10 ET | Arcutis Biotherapeutics, Inc.
Arcutis today announced the commencement of an underwritten public offering of $150.0 million of shares of its common stock
Arcutis logo.png
Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan
February 28, 2024 16:00 ET | Arcutis Biotherapeutics, Inc.
Arcutis and Sato today announced that the companies have entered into a strategic collaboration and licensing agreement for topical roflumilast in Japan.